In vitro long-term proliferation assays to study antiproliferative effects of PARP inhibitors on cancer cells

1Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Cell proliferation assays are an important component of small molecule inhibitor screens for cancer therapies. An important but often overlooked variable involves the timing and timeframe of inhibitor treatment. Whereas many traditional chemotherapeutics kill or inhibit proliferation on the timeframe of hours or in a few days of treatment, more targeted therapies that affect other cancer-relevant pathways, including differentiation or cell stress responses, can take longer, often several days to weeks to impact cellular growth and survival. Many poly(ADP-ribose) polymerases (PARPs) are involved in cellular stress pathways; therefore, phenotypic effects of PARP inhibition are often only observed with long-term inhibitor treatment. Here we summarize several assays for analyzing long-term proliferation of both adherent and suspension cells, relying either on growth in two-dimensional tissue culture or on systems than enable growth in 3D.

Cite

CITATION STYLE

APA

Keilhack, H., & Chang, P. (2017). In vitro long-term proliferation assays to study antiproliferative effects of PARP inhibitors on cancer cells. In Methods in Molecular Biology (Vol. 1608, pp. 321–336). Humana Press Inc. https://doi.org/10.1007/978-1-4939-6993-7_21

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free